ALZN - Alzamend Neuro, Inc.

1.98
0.030   1.515%

Share volume: 29,857
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$1.95
0.03
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 43%
Liquidity 49%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.49%
1 Month
0.51%
3 Months
-12.00%
6 Months
-16.10%
1 Year
160.53%
2 Year
86.79%
Key data
Stock price
$1.98
P/E Ratio 
0.00
DAY RANGE
$1.89 - $2.02
EPS 
-$55.49
52 WEEK RANGE
$0.51 - $8.22
52 WEEK CHANGE
$179.38
MARKET CAP 
6.107 M
YIELD 
N/A
SHARES OUTSTANDING 
841.240 K
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
BETA 
1.89
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$41,989
AVERAGE 30 VOLUME 
$74,813
Company detail
CEO: Stephan Jackman
Region: US
Website: alzamend.com
Employees: 4
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Recent news